/Dale Yuzuki

About Dale Yuzuki

A sales and marketing professional in the life sciences research-tools area, Dale currently is employed by Singlera Genomics as an Assoc Director of Business Development. He will help Singlera forge partnerships in using their novel methylation haplotype from cell-free DNA to examine blood-based assays for early disease diagnostics development. He also represents Singlera at tradeshows and other events. For additional biographical information, please see my LinkedIn profile here: http://www.linkedin.com/in/daleyuzuki and also find me on Twitter @DaleYuzuki.

Single molecule detection of ctmDNA

By |2018-11-12T06:59:36+00:00November 12th, 2018|

Singlera detects single molecules of ctmDNA Single molecule detection of ctmDNA The reason why early detection biomarkers for cancer is not a trivial task First, second and third-generation sequencing First-generation sequencing (also known as Sanger sequencing, or dideoxy-terminator sequencing) was the technology used for the Human Genome Project, and remains a workhorse and [...]

Obtain many circulating biomarkers broadly, or a few biomarkers deeply?

By |2018-11-08T08:03:07+00:00November 8th, 2018|

A ribbon model of molecules of protein p53 binding to a strand of DNA.         Obtain many circulating biomarkers broadly, or a few biomarkers deeply? Can you have it all? At the recent Society for Neuroscience, Abcam sponsored a workshop entitled "Biomarkers of Neuroinflammation in Parkinson’s Disease" where Dr. Nicole [...]

Why isn’t cancer prevention a higher priority?

By |2018-11-05T06:19:48+00:00November 5th, 2018|

Why isn't cancer prevention a higher priority? Cancer death rates could be drastically reduced Cancer is the second leading cause of death worldwide. In a recent issue of the journal Science (Sept 28 2018, Vol 361 Issue 6409 page 1317, "Cancer Prevention: Molecular and epidemiologic consensus" Song M and Tomasetti C et al. ref 1) [...]

What if circulating tumor methylated DNA from brain cancer could be detected?

By |2018-11-06T02:51:21+00:00October 29th, 2018|

A group of CAT scans of the human brain What if circulating tumor methylated DNA from brain cancer could be detected? Can ctmDNA be an early detection tool for glioblastoma multiforme? Gliblastoma Multiforme is a terrible form of brain cancer. With a reported 5-year survival rate of only 4.4%, at just the 3-year [...]

Circulating Biomarkers: the Internet of Biology

By |2018-11-06T02:52:33+00:00October 26th, 2018|

Circulating Biomarkers: the Internet of Biology Signals within the remarkable circulatory system A few weeks ago learning about a new San Diego CA company called Cardea Biosciences they described a novel functionalized graphene biosensor with the tagline, ‘Powering the Internet of Biology’. This is a powerful metaphor – the Internet is seen as a ‘fourth [...]

The Challenges and Opportunities of Prospective Longitudinal Studies

By |2018-11-06T02:53:18+00:00October 24th, 2018|

The Challenges and Opportunities of Prospective Longitudinal Studies Is it possible to accelerate the future? What is exciting about working in the field of clinical molecular diagnostics is its promise of real impact on human health. Yet the path from biomarker discovery to an FDA-approved test in general use is a long and painstaking process: [...]

Why use circulating tumor methylated DNA (ctmDNA) to detect disease?

By |2018-11-06T02:54:55+00:00October 22nd, 2018|

Why use circulating tumor methylated DNA (ctmDNA) to detect disease? Circulating tumor DNA (ctDNA) isn’t abundant enough for subtle signals from circulating DNA History and context of cell-free DNA and its role in cancer In 1949 Mandel and Matais discovered cell-free DNA in plasma in a French publication and in 1965 (seventeen years [...]

Looking for new circulating biomarker signals with new technology

By |2018-10-21T11:43:51+00:00October 21st, 2018|

Looking for new circulating biomarker signals with new technology Note: A version of this post was previously published on The Next Generation Technologist blog. Cell-free DNA is an attractive analyte For those not too familiar with cell-free DNA, this is DNA shed from natural (or unnatural) cell death and typically is cleared from [...]

An Early Mark: Announcing the Singlera Genomics Blog

By |2018-11-06T02:56:48+00:00October 21st, 2018|

An Early Mark: Announcing the Singlera Genomics Blog Singlera Genomics has been established with the most elusive of goals: to detect disease early, through a gene signature that can be as easy as a blood test. Through analysis of circulating methylated DNA markers in the bloodstream rather than specific DNA mutations, the numbers [...]

Good things come to those who sign up for
An Early Mark
Join our email list to get the latest blog posts straight to your inbox
SUBSCRIBE
Give it a try, you can unsubscribe anytime.
close-link